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Abstract
Purpose Ceritinib is an ALK receptor tyrosine kinase inhibitor approved as first- and second-line treatment in adult patients
with ALK + metastatic non-small cell lung cancer (NSCLC). The study investigated the drug–drug interaction (DDI) potential of ceritinib when coadministered with midazolam and warfarin as probe substrates for CYP3A and CYP2C9 activity,
respectively.
Methods This was a phase I, multicenter, open-label, single sequence, crossover DDI study in 33 adult patients with
ALK + NSCLC or other advanced tumors. A single dose of a cocktail consisting of midazolam and warfarin was administered
with and without concomitant administration of ceritinib. The primary objective was to evaluate the pharmacokinetics of
midazolam and warfarin. Secondary objectives included pharmacokinetics, safety, tolerability, overall response rate (ORR),
and duration of response (DOR) of ceritinib 750 mg once daily.
Results Ceritinib inhibited CYP3A-mediated metabolism of midazolam, resulting in a markedly increased AUC (geometric
mean ratio [90% confidence interval]) by 5.4-fold (4.6, 6.3). Ceritinib also led to an increase in the AUC of S-warfarin by
54% (36%, 75%). The pharmacokinetics and safety profile of ceritinib in this study are consistent with previous reports and
no new safety signals were reported. Among the 19 patients with NSCLC, efficacy (ORR: 42.1% and DCR: 63.2%) was
similar to that reported previously in studies of pretreated patients with ALK + NSCLC.
Conclusion Ceritinib is a strong CYP3A inhibitor and a weak CYP2C9 inhibitor. These findings should be reflected as
actionable clinical recommendations in the prescribing information for ceritinib with regards to concomitant medications
whose pharmacokinetics may be altered by ceritinib.
Keywords ALK inhibitor · Ceritinib · Drug–drug interaction · Pharmacokinetics · CYP3A · CYP2C9 · Midazolam ·
Warfarin
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Introduction
Anaplastic lymphoma kinase (ALK)-rearrangements are
a key oncogenic driver, implicated in the pathogenesis of
several human cancers [1]. In non-small-cell lung cancer
(NSCLC), ALK-rearrangements have been reported in
approximately 3–7% of patients [2, 3].
Ceritinib (LDK378, Zykadia®; Novartis Pharmaceuticals
Corporation) is an orally available ALK inhibitor, approximately 20-fold more potent than crizotinib [4]. Ceritinib is
approved at a dose of 450 mg taken orally once daily (QD)
with food for the treatment of patients with metastatic ALKpositive NSCLC [5]. In randomized, global phase III trials,
ceritinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival
vs. chemotherapy in patients with advanced ALK-positive
NSCLC who were treatment-naïve (ASCEND-4 study) [6]
or previously treated with crizotinib and one or two prior
chemotherapy regimens (ASCEND-5 study) [7].
Ceritinib is primarily cleared by hepatic oxidative metabolism via CYP3A (> 90%) as demonstrated in in vitro human
liver microsome (HLM) studies. The metabolic drug–drug
interaction (DDI) potential of ceritinib as an inhibitor of
CYP metabolizing enzymes was evaluated in vitro by incubation with pooled HLMs. Ceritinib competitively inhibited the metabolism of midazolam (CYP3A substrate) and
diclofenac (CYP2C9 substrate). Furthermore, ceritinib is a
reversible and time-dependent inhibitor of CYP3A (maximum rate of inactivation [kinact]: 0.0642 min-1; inhibitor
concentration associated with 50% maximal inactivation rate
[Ki]: 1.47 μM), but shows no apparent time-dependent inhibition of CYP1A2, 2C9, or 2D6 at ceritinib concentrations
up to 50 µM. Ceritinib is unlikely to inhibit CYP1A2, 2B6,
2C8, 2C19, or 2D6 at clinically relevant concentrations [8].
Inhibition of CYP3A- and CYP2C9-mediated metabolism by ceritinib can lead to a decreased rate of elimination of concomitantly administered drugs that are primarily
metabolized by these isoforms, resulting in an increased
systemic exposure and potential toxicity, especially for
those drugs that have a narrow therapeutic index (NTI). To
provide actionable labeling recommendations to healthcare
practitioners for safe and effective use of co-administered
CYP3A and 2C9 substrates with ceritinib, the extent of CYP
inhibition by ceritinib needs to be further characterized considering the potential of clinically relevant drug interactions.
Evaluation of a candidate drug’s potential for in vivo
induction or inhibition of CYPs and transporters by the
administration of a drug cocktail allows simultaneous
assessment of multiple drug–substrate interactions under
controlled conditions [9–11]. Turpault et al. [10] reported
the absence of pharmacokinetic interaction between warfarin (CYP2C9 substrate) and midazolam (CYP3A substrate)

13

when administered concurrently in a clinical trial conducted
in healthy male subjects. Since CYP3A subfamily enzymes
are predominantly expressed in the liver and intestine in
humans, co-administration of oral ceritinib may alter both
intestinal absorption and fraction escaping hepatic metabolism (i.e., bioavailability) of an orally administered CYP3A
substrate. As a result, oral rather than intravenous midazolam was the preferred route of administration in this study.
This study was designed to evaluate the potential inhibitory effects of ceritinib on the CYP3A- and CYP2C9-mediated metabolism of the probe drugs midazolam and warfarin, respectively, when administered simultaneously as a
cocktail in patients with ALK-positive tumors. The results of
this clinical trial provided evidence on how to dose CYP3A
and 2C9 substrates when administered concomitantly with
ceritinib.

Materials and methods
Study population
Adult patients (≥ 18 years) with confirmed stage IIIB or
IV ALK-positive NSCLC or an advanced tumor other than
NSCLC that carried an ALK genetic alteration were eligible
to participate in the study. ALK positivity was determined
locally using an approved test. Other inclusion criteria
included a World Health Organization performance status
(WHO PS) of 0–2, adequate organ function as assessed by
laboratory test results, and asymptomatic or neurologically
stable central nervous system metastases. Eligible patients
were either treatment-naïve or were previously treated
with ≥ 1 systemic anticancer therapy (including chemotherapy, other ALK inhibitors, or immunotherapy).
Usage of concomitant drugs that could confound the
study results or expose patients to risk for drug-related toxicity had to be discontinued ≥ 4 weeks prior to study start
and for the duration of the study, including but not limited
to strong inhibitors or inducers of CYP3A and/or CYP2C9,
medications with a low therapeutic index that are primarily metabolized by CYP3A and/or CYP2C9, and medications with a known risk of causing QT prolongation and/
or Torsades de pointes. Patients who consumed alcohol
(regular daily intake ≥ 1 drink/day) or grapefruit/grapefruit
juice ≤ 3 days prior to pharmacokinetic blood sample collection were also excluded.

Study design
This was a multicenter, open-label, single sequence,
crossover phase I study (ClinicalTrials.gov identifier:
NCT02422589) and was divided into two phases, DDI
phase and post-DDI treatment phase (Fig. 1). Patients were
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Screening

DDI phase (Days 1 to 34)

Post-DDI phase

Day 1

Day 28

Midazolam (CYP3A)
Warfarin (CYP2C9)

Midazolam (CYP3A)
Warfarin (CYP2C9)

Days 1 to 6

Day 7, Day 8, Day 9 [...]

Days 28* to 34

Probe alone

Probe + ceritinib

AUC0-144h

AUC0-144h

21-day cycles [...]
Ceritinib dosing (750 mg QD)

Midazolam + warfarin dosing**

Fig. 1  Study design. *Ceritinib steady-state was reached by Day 28
following 3 weeks of daily dosing (see Figure S2). **Midazolam
and warfarin administered as a single oral dose of 2.5 mg and 10 mg,

respectively. AUC area under the plasma concentration–time curve,
DDI drug–drug interaction, QD once daily

recruited from 10 clinical centers located across 4 countries,
namely Spain (n = 3), United States (n = 3), Italy (n = 3), and
Denmark (n = 1). On Day 1 of the DDI phase, patients were
administered a single dose of the probe drug cocktail comprising warfarin (10 mg) and midazolam (2.5 mg) and a
full pharmacokinetic profile for each probe drug was collected over 144 h post-dose. Ceritinib (750 mg orally QD
under fasted conditions) was administered continuously
for 3 weeks starting from Day 7 following the collection
of last pharmacokinetic blood sample to reach steady-state
and hence max out the inhibitory effect towards CYPmetabolizing enzymes. On Day 28, patients received a dose
of 750 mg ceritinib and a concomitant single dose of the
midazolam + warfarin cocktail, followed by collection of a
full pharmacokinetic profile. The individual pharmacokinetic profiles of probe drugs administered on Day 28 were
compared to those acquired on Day 1 to assess the extent of
CYP3A and CYP2C9 inhibition by ceritinib.
Upon completion of the DDI phase on Day 34, patients
entered the post-DDI phase and continued to be treated
with ceritinib at a dose of 750 mg QD on continuous 21-day
cycles until unacceptable toxicity, disease progression, withdrawal of consent, or at the discretion of the investigator.
Patients were allowed to receive treatment with ceritinib following disease progression if, in the opinion of the investigator, continued treatment provided clinical benefit. Ceritinib
dose reductions (150 mg/day per dose reduction step, up to
the minimum allowed dose of 300 mg/day) were permitted
for patients who did not tolerate the 750 mg/day starting
dose.
The primary objective of the study was to evaluate the
pharmacokinetics of midazolam and warfarin, with and
without concomitant administration of ceritinib. Secondary
objectives were to assess the pharmacokinetics, safety, tolerability, and antitumor activity (by means of overall response

rate [ORR] and duration of response [DOR]) of ceritinib in
patients with advanced ALK-positive tumors.
The ceritinib dose chosen for this study was 750 mg QD
fasted, which was the dose used in the pivotal clinical study
that served as basis for the regulatory approval of ceritinib
in ALK + NSCLC, as well as the original dose approved in
most countries. On the basis of pharmacokinetics, safety,
and efficacy results from a post-marketing dose optimization study conducted in ALK + NSCLC patients [15, 16]
(ASCEND-8 study), the recommended dose of ceritinib
was changed to 450 mg QD with food. The data acquired
in ASCEND-8 study demonstrated equivalent steady-state
exposure of ceritinib between 450 mg QD with food vs.
750 mg QD fasted, in addition to the 450 mg with food
dose having the more favorable gastrointestinal safety profile with similar efficacy to 750 mg fasted. Therefore, the
results generated in the present DDI study (which used ceritinib 750 mg QD fasted) pertaining to changes in exposure
of co-administered CYP3A and 2C9 substrates are directly
applicable to the newly approved dose of ceritinib 450 mg
QD with food.
The study was designed and conducted in accordance
with the ethical principles of the Declaration of Helsinki and
the guidelines for Good Clinical Practice, with applicable
local regulations. The study protocol and all amendments
were reviewed by an independent ethics committee or institutional review board for each center. All patients provided
written informed consent before screening.

Assessments
To assess the pharmacokinetics of probe substrates, blood
samples were obtained on Days 1 and 28 at pre-dose and
at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, and
144 h post-dose. Additional blood samples were obtained
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at pre-dose on Days 28, 29, 30, 31, 32, 33, and 34 to assess
steady-state pharmacokinetics of ceritinib. Plasma concentrations of ceritinib were measured by a validated liquid chromatography-tandem mass spectrometry (LC–MS/
MS) assay with a lower limit of quantification (LLOQ) of
1.00 ng/mL using 100 µL of human plasma [12]. Plasma
concentrations of midazolam, 1′-hydroxymidazolam (LLOQ
of 0.100 ng/mL), S-warfarin, R-warfarin, and 7-hydroxy-Swarfarin (LLOQ of 2.00 ng/mL) were also determined using
validated LC–MS/MS assays. Pharmacokinetic parameters
of midazolam, warfarin, and their metabolites were determined by non-compartmental analysis using Phoenix WinNonlin version 6.4 (Certara Inc., Princeton, NJ, USA). A
blood sample for CYP2C9 genotyping was collected on Day
1 of the DDI phase from all participating patients. Patients
were categorized as CYP2C9 poor, intermediate, or extensive metabolizers based on the genotype testing results. This
assessment was of exploratory nature and was not used as
inclusion/exclusion criteria in the study.
Adverse events (AEs) were coded using the Medical
Dictionary for Regulatory Activities version 20.1 and were
graded using Common Terminology Criteria for Adverse
Events version 4.03. All patients were followed up for AEs
and serious AEs (SAEs) for at least 30 days following the
last dose of study treatment at the end of treatment phase.
Tumor evaluation was performed at screening visit within
28 days prior to study treatment (Day 1 of DDI phase) using
contrast enhanced computed tomography (or magnetic resonance imaging). Assessments of tumor response were performed every two cycles (i.e., every 6 weeks) through Cycle
9. ORR and DOR by investigator assessment was reported
per Response Evaluation Criteria in Solid Tumors (RECIST)
1.1.

Statistical analysis
A sample size of 18 patients with evaluable pharmacokinetic data was determined to provide reasonable precision in
the estimation of geometric mean ratio (GMR) assuming the
intra-subject CV of warfarin (20%) and midazolam (18.5%)
pharmacokinetics. Due to the strict evaluability criteria and
the requirement to conduct the study with repeat daily doses
of ceritinib, the total number of patients enrolled was targeted to be approximately 35 in order to obtain at least 18
evaluable patients.
The pharmacokinetic analysis set for midazolam and warfarin consisted of all patients who had an evaluable pharmacokinetic profile from both periods (CYP substrate alone
and CYP substrate + ceritinib). The criteria used to consider
an individual pharmacokinetic profile to be non-evaluable
included major deviations in the originally assigned dosing schedule of ceritinib, vomiting within 4 h after dosing,
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among other pre-defined criteria included in the study statistical analysis plan.
A formal statistical analysis was carried out to compare
the single-dose pharmacokinetics of the probe substrates
before and after ceritinib administration. A linear mixedeffects model was fitted to the log-transformed primary PK
parameters (Cmax, AUC0-144 h, and AUC0-inf) and included
a fixed effect for treatment and a random effect for subject.
For the statistical analysis, midazolam/warfarin + ceritinib
was the test treatment and midazolam/warfarin alone the
reference. The model-based, between-treatment mean differences (probe substrate + ceritinib–probe substrate alone)
and corresponding two-sided 90% confidence intervals (CIs)
were calculated on the log-scale. The between-treatment differences and 90% CIs were then back-transformed to the
original scale to obtain the geometric mean ratios (probe
substrate + ceritinib/probe substrate alone) and corresponding 90% CIs.

Results
Patient disposition
A total of 33 patients were enrolled in the study; of these,
18 (54.5%) completed the DDI phase. Of the 15 patients
who discontinued the DDI phase, 12 patients permanently
discontinued from the study, and 3 remained on ceritinib
treatment. The majority of patients discontinued from the
DDI phase due to AEs or progressive disease (Table S1).
All 33 patients received ≥ 1 dose of any study medication
and were included in the efficacy and safety analysis sets.
Twenty patients (60.6%) were included in the pharmacokinetic analysis set.

Patient demographics and disease characteristics
The median age of the patients was 57 years (range 22–78),
and most were female (63.6%), Caucasian (97.0%), and had
a WHO PS of 0 or 1 (94.0%). Baseline patient demographics and disease characteristics for all patients are shown in
Table 1. The disease characteristics of patients in this study
were representative of the population of patients with ALKpositive tumors. The majority of the patients had NSCLC
(57.6%), the target indication of ceritinib, and the most common histology/cytology was adenocarcinoma (63.6%). All
patients entered the study with stage IV or IVB disease.
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Table 1  Patient demographics and disease characteristics at baseline
Characteristic

All patients
N = 33
n (%)

Median age (range), years
Sex, n (%)
Female
Male
Race, n (%)
Caucasian
Unknown
WHO performance status, n (%)
0
1
2
Smoking history, n (%)
Current smoker
Former smoker
Never smoked
Primary site of cancer, n (%)
Lung
Other
Bone, other
Skin
Soft tissue
Abdominal mass
Kidney
Pelvic
Histology/cytology, n (%)
Adenocarcinoma
Other
Stage at study entry, n (%)
IV
IVB
Median time from primary diagnosis to enrolment
(range), months
Number of prior regimens, n (%)
0
1
2
≥3
Prior anti-cancer medications, n (%)
Chemotherapy
ALK inhibitors
Ceritinib
Crizotinib
Checkpoint inhibitors
Ipilimumab
Nivolumab
Pembrolizumab

57.0 (22–78)
21 (63.6)
12 (36.4)
32 (97.0)
1 (3.0)
16 (48.5)
15 (45.5)
2 (6.1)
2 (6.1)
14 (42.4)
17 (51.5)
19 (57.6)
5 (15.2)
2 (6.1)
2 (6.1)
2 (6.1)
1 (3.0)
1 (3.0)
1 (3.0)
21 (63.6)
12 (36.4)
32 (97.0)
1 (3.0)
22.41 (1.1–185.0)

3 (9.1)
6 (18.2)
9 (27.3)
15 (45.5)
24 (72.7)
1 (3.0)
12 (36.4)
2 (6.1)
6 (18.2)
1 (3.0)

ALK anaplastic lymphoma kinase, WHO World Health Organization

Effect of 750 mg QD ceritinib
on the pharmacokinetics of midazolam (CYP3A
probe substrate)
Midazolam exposure increased markedly when co-administered with ceritinib, reflecting an inhibitory effect towards
CYP3A activity (Fig. 2). The estimated GMR (90% CI)
(midazolam + ceritinib vs. midazolam alone) of midazolam AUC0-inf and Cmax were 5.42 (4.64, 6.34) and 1.82
(1.54, 2.16), respectively (Table S2). The median time to
peak plasma concentration (Tmax) of midazolam remained
unaffected by ceritinib and was reached at approximately
1 h after dosing. Given an increase in midazolam AUC
of ≥ 5-fold, these results indicate that ceritinib is a strong
inhibitor of CYP3A in the target patient population.
A notable decrease by approximately 80% in the apparent
clearance (CL/F) of midazolam (from 34.5 L/h [midazolam
alone] to 6.36 L/h [midazolam + ceritinib]) as well as a prolongation of its elimination half-life (T1/2) from 6 to 15 h
confirms the inhibitory effect of ceritinib towards CYP3A.
The geometric mean metabolite-to-parent AUC ratio for
1′-hydroxymidazolam (metabolite formed by midazolam
1′-hydroxylation, CYP3A-mediated) decreased from 19.3%
(midazolam alone) to 2.9% (midazolam + ceritinib), evidencing a notable reduction in CYP3A-mediated metabolism of
midazolam in the presence of ceritinib (Table 2).

Effect of 750 mg QD ceritinib
on the pharmacokinetics of warfarin (CYP2C9 probe
substrate)
Warfarin is a racemic mixture of S- and R-enantiomers, the
former exhibiting 5–6 times greater anticoagulant potency.
Hence, pharmacokinetic changes of S-warfarin served as
the basis to inform dosing recommendations pertaining
co-administration of ceritinib with CYP2C9 substrates,
as the pharmacological effect of warfarin resides mainly
in S-warfarin. Overall, S-warfarin plasma concentrations
were increased in the presence of ceritinib, although the
magnitude of increase was not as high as that observed for
midazolam (Fig. 2).
The estimated GMR (90% CI) (warfarin + ceritinib vs.
warfarin alone) of S-warfarin AUC0-inf and Cmax were 1.54
(1.36, 1.75) and 1.05 (0.912, 1.21), respectively (Table S2).
These results indicate that ceritinib is a weak inhibitor
of CYP2C9. Although the extent of exposure increase of
S-warfarin was < 2-fold, an increase of AUC by 54% is considered clinically relevant, considering warfarin is a widely
prescribed anticoagulant for chronic use to treat and/or prevent thromboembolic events in patients and minimal concentration changes in the blood may lead to serious safety concerns. There was no apparent change in the onset of warfarin
absorption. S-warfarin CL/F was reduced by approximately
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A

Arithmetic mean

Mean (SD) plasma midazolam concentration (ng/mL)

midazolam
midazolam+ceritinib

Treatment

Geometric mean

midazolam
midazolam+ceritinib

midazolam
midazolam+ceritinib

100

10

1

0.1

012 4

B

8

24

Arithmetic mean
warfarin
warfarin+ceritinib

48

72

Time (hour)

96

120

144

Treatment

Geometric mean

warfarin
warfarin+ceritinib

warfarin
warfarin+ceritinib

Mean (SD) plasma S-warfarin concentration (ng/mL)

1000

100

10

1
012 4

8

24

48

72

Time (hour)

96

120

144

Fig. 2  Geometric mean and arithmetic mean (standard deviation)
concentration–time profiles depicting the effect of ceritinib on the
pharmacokinetics of co-administered CYP3A and CYP2C9 sub-

strates. A Midazolam with and without ceritinib. B S-warfarin with
and without ceritinib. SD standard deviation

30% and T1/2 prolonged from 43 to 55 h when co-administered with ceritinib. The geometric mean metabolite-toparent AUC ratio for 7-hydroxy-S-warfarin (a marker for
S-warfarin 7-hydroxylation, CYP2C9-mediated) decreased

from 14.3% (warfarin alone) to 11.7% (warfarin + ceritinib),
indicating a modest reduction in CYP2C9-mediated metabolism of warfarin in the presence of ceritinib. Ceritinib did
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23.0 (56.2)
42.0 (39.3)
5.41 (74.1)
1.90 (73.8)
569 (34.9)
599 (27.5)
560 (34.2)
616 (23.6)
39.7 (60.3)
34.9 (61.6)

20
20
20
20
20
20

Cmax (ng/mL)

20
20
20
20

N

18,200 (46.6)
28,400 (36.0)
30,600 (39.0)
38,500 (34.9)
2910 (61.8)
3320 (64.1)

70.2 (46.7)
387 (37.0)
14.7 (74.4)
12.1 (87.0)

AUC0–144 h (h*ng/
mL)

CL/F (L/h)

1.47 [0.483; 3.92]
2.75 [0.250; 6.40]
1.98 [0.483; 21.7]
2.83 [0.250; 71.2]
24.2 [2.97; 49.9]
47.2 [8.50; 73.7]

0.471 (28.1)
0.346 (22.8)
0.277 (15.6)
0.267 (37.6)

0.500 [0.217; 1.00] 34.5 (45.8)
0.750 [0.250; 2.53] 6.36 (35.9)
0.500 [0.217; 2.00]
0.583 [0.250; 2.53]

Tmax (h)

42.9 (30.9)
55.4 (44.5)
62.2 (24.6)
77.1 (30.5)

6.05 (47.8)
15.4 (37.4)

T1/2 (h)

14.3 (66.6)
11.7 (58.2)

19.3 (66.3)
2.89 (66.7)

Metabolite-to-parent
ratio (%)a

a

Metabolite-to-parent ratio = [(metabolite AUC0–144 h/metabolite molecular weight)/(parent AUC0–144 h / parent molecular weight)] × 100

Cmax: maximum plasma concentration observed; AUC0–144 h: area under the plasma concentration–time curve t = 0–144 h; Tmax: time to reach Cmax; CL/F: apparent clearance; T1/2: elimination
half-life; N: number of subjects included in the analysis

CV% geometric mean = sqrt[exp(variance for log-transformed data) – 1] × 100

Parameters reported as geometric mean (CV%); Tmax reported as median [min; max]

CYP3A
Midazolam
Midazolam + ceritinib
1′-hydroxymidazolam
1′-hydroxymidazolam + ceritinib
CYP2C9
S-warfarin
S-warfarin + ceritinib
R-warfarin
R-warfarin + ceritinib
7-Hydroxy-S-warfarin
7-Hydroxy-S-warfarin + ceritinib

CYP probe substrate

Table 2  Summary of pharmacokinetic parameters for midazolam, warfarin, and their major metabolites, with and without concurrent administration of ceritinib
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Table 3  Patient disposition by CYP2C9 metabolizer subtype
Phenotype

Examples of genotypes

Clinical implicationa

Frequency, n (%)
(N = 33)

Extensive metabolizer
Intermediate metabolizer

CYP2C9*1/*1
CYP2C9*1/*3, *1/*2

17 (51.5)
12 (36.4)

Poor metabolizer
Unknownb

CYP2C9*2/*2, *3/*3, *2/*3
–

Normal enzyme activity
Intermediate enzyme activity, highly variable among individuals
Low or deficient enzyme activity
–

a
b

1 (3.0)
3 (9.1)

Based on guideline reported by Caudle et al. [17]
Unknown status due to blood specimen not collected and/or genotype testing not performed

not affect the pharmacokinetics of R-warfarin to a clinically
significant extent (Table 2, Figure S1).
Patient disposition by CYP2C9 metabolizer subtype is
shown in Table 3. The majority of the patients were categorized as CYP2C9 extensive metabolizers (51.1%), followed
by intermediate metabolizers (36.4%). Only one patient
(< 5%) was identified as being CYP2C9 poor metabolizer
(PM). By definition, CYP2C9 PM individuals might be
inherently insensitive to DDI in the presence of a (strong)
inhibitor of CYP2C9. All subjects but one had an increase
in S-warfarin AUC0-144 h on Day 28 (warfarin + ceritinib)
relative to Day 1 (warfarin alone) regardless of CYP2C9
phenotype; a similar trend was less apparent for the metabolite 7-hydroxy-S-warfarin (Figure S3). The presence of
only 1 PM in the study population precludes any definitive

Fig. 3  Forest plot illustrating the inhibitory effect of ceritinib on the
metabolism of midazolam and warfarin (geometric mean ratio and
90% confidence interval). Dashed vertical lines denote the 0.8 to 1.25
reference interval used to inform dosing recommendations. Refer to
Table S2 for a tabular summary of the results. Dosing regimen: mida-
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conclusion about the impact of CYP2C9 genetic polymorphisms, particularly of the less prevalent PM phenotype, on
the magnitude of DDI between ceritinib and concomitant
medications that are substrates of CYP2C9.

Pharmacokinetics of ceritinib (perpetrator drug)
The average pre-dose (trough) concentration–time profile
for ceritinib is shown in Figure S2. On the basis of trough
concentrations in plasma after repeated daily dosing,
steady-state drug exposure was reached on Day 28 following 3 weeks of dosing and remained stable afterwards
(geometric mean Ctrough ranging between 767 and 1040 ng/
mL). The results are in line with the known pharmacokinetic properties of ceritinib in crizotinib-naïve and crizotinib pre-treated ALK + NSCLC patients at the 750 mg/day
fasted dosing regimen [13].

zolam administered as a 2.5 mg single dose; warfarin administered as
a 10 mg single dose; ceritinib administered orally at 750 mg QD for
3 weeks. AUC area under the plasma concentration–time curve, Cmax
maximum plasma concentration
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Summary of pharmacokinetic inhibition of CYP3A‑
and CYP2C9‑mediated metabolism by ceritinib
A forest plot illustrating the effect of ceritinib on the
pharmacokinetics of selected CYP3A and CYP2C9 probe
substrates is provided in Fig. 3. Changes in systemic exposure of midazolam and S-warfarin were primarily used to
inform dosing recommendations in the local prescribing
information for ceritinib, including USPI and EU SmPC.

Safety and efficacy of ceritinib
Safety
The median duration of treatment exposure was 10.14 weeks
(range: 0.4–82.4). AEs were reported in 32 (97%) patients;
of these, 29 (87.9%) patients had AEs suspected to be study
drug related. The most frequently reported AEs regardless
of study drug relationship for all patients (≥ 10 patients for
all grades) were diarrhea (75.8%), nausea (60.6%), vomiting
(51.5%), increased ALT (36.4%), increased GGT (33.3%),
increased AST (30.3%), increased ALP (30.3%), and asthenia (30.3%). Grade 3 or 4 AEs suspected to be study drug
related were reported in 16 patients (48.5%); the most common (≥ 10%) suspected grade 3/4 AEs were increases in
ALT (24.2%), GGT (18.2%), and AST (12.1%) (Table S3).
Six patients (18.2%) discontinued treatment due to AEs; the
most common AEs leading to study discontinuation were
diarrhea (12.1%), nausea (9.1%), vomiting (6.1%), and
fatigue (6.1%).
In total, 8 patients died during the study; of these, 4
deaths occurred during the on-treatment period (within
30 days of last dose of ceritinib). None of the deaths were
suspected to be treatment related. The cause of all 8 deaths
was study disease. Serious AEs were reported in 13 (39.4%)
patients, with 11 patients (33.3%) reporting grade 3/4 SAEs.
Only 3 patients (9.1%) had SAEs suspected to be related to
study drug.

Efficacy
Overall, ORR was 27.3% (95% CI: 13.3, 45.5) and DCR was
45.5% (95% CI: 28.1, 63.6). Among the 19 patients with
NSCLC, ORR was 42.1% (95% CI: 20.3, 66.5), and DCR
was 63.2% (95% CI: 38.4, 83.7) (Table S4). The median
DOR was not evaluable.

Discussion
On the basis of early in vitro evidence suggesting that ceritinib may inhibit CYP3A and 2C9 at clinical concentrations, the initial recommendation was to avoid concurrent
use of CYP3A and 2C9 substrates known to have narrow therapeutic indices or substrates primarily metabolized by CYP3A and 2C9 during treatment with ceritinib,
unless dose reduction of the substrate(s) was considered.
Furthermore, experimental I C50 and Ki values for ceritinib inhibition of CYP3A (midazolam as substrate) and
2C9 activity (diclofenac as substrate) in HLM relative
to the C max of ceritinib at steady-state, observed in the
first-in-human study, provided early evidence of a clinical drug interaction potential. In light of the potential of
ceritinib to increase the systemic exposure of concomitant
CYP3A and 2C9 substrates at the recommended dose, a
confirmatory clinical DDI study was conducted in patients
with cancer to allow for a more definitive determination
on dosing concomitant CYP3A and 2C9 substrates with
ceritinib. This phase I, multi-center, open-label, single
sequence, crossover study evaluated the effect of repeat
daily doses of ceritinib on the pharmacokinetics of the
probe substrates midazolam and warfarin administered as
a two-drug cocktail, which are metabolized by CYP3A
and 2C9, respectively. A total of 33 adult patients with
advanced cancers harboring genetic alterations in ALK
including NSCLC participated in the study.
In vitro studies utilizing HLM revealed that ceritinib
reversibly inhibits CYP3A4/5 ( IC50 = 0.2 µM, Ki = 0.16 µM)
and CYP2C9 (IC50 = 2 µM, Ki = 0.24 µM), among other
CYPs of more minor clinical relevance including CYP2A6,
2B6, and 2D6 [8]. Considering a Cmax at steady-state of
1010 ng/mL (or 1.8 µM) observed in earlier clinical trials,
the potential for ceritinib to inhibit the metabolism of coadministered CYP3A/2C9 substrates at clinically-relevant
doses needed to be further investigated. As ceritinib exhibits
nonlinear, time-dependent pharmacokinetics in humans, the
latter likely a result of auto-inhibition of CYP3A, [8, 14]
ceritinib was dosed repeatedly at 750 mg/day for 3 weeks
to promote maximum inhibition of CYP3A/2C9 prior to
administration of the midazolam + warfarin cocktail on Day
28, and was continued during the midazolam/warfarin elimination phase (Days 28–34). T
The need for repeat doses of ceritinib in the current DDI
study was also supported by physiology-based pharmacokinetic (PBPK) model simulations of the effect of ceritinib on
the exposure of midazolam, a sensitive CYP3A substrate.
The PBPK model predicted much greater magnitudes of
pharmacokinetic interaction when ceritinib was administered
to steady-state as compared to single dose ceritinib; when a
single dose of ceritinib (750 mg) was co-administered with
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a single oral dose of midazolam (5 mg), midazolam AUC
increased by only 30%, whereas when ceritinib was dosed to
steady-state, midazolam AUC following a single oral dose
(5 mg) was predicted to increase by 6-fold [8]. Ceritinib
is both a substrate and time-dependent inhibitor of human
CYP3A in vitro. Because ceritinib features time-dependent
clearance in patients, presumably a result of auto-inhibition
of CYP3A-mediated metabolism, the smaller change in
midazolam exposure with a single ceritinib dose is attributed to incomplete inhibition of CYP3A. Considering that
ceritinib achieves steady-state within 2–3 weeks following
repeat daily dosing with an accumulation ratio of 6, [8]
CYPs are expected to be inhibited to their full extent only
after multiple daily doses of ceritinib.
Coadministration of ceritinib increased the AUC of midazolam by 5.42-fold (90% CI: 4.64, 6.34) and Cmax by 1.82fold (90% CI: 1.54, 2.16) compared to midazolam administered alone, indicating that ceritinib is a strong inhibitor of
CYP3A. Furthermore, an 85% decrease in the metaboliteto-parent AUC ratio for 1′-hydroxymidazolam was observed,
further confirming a strong inhibitory effect on CYP3Amediated metabolism of midazolam in the presence of ceritinib. All in all, these results are consistent with the in vitro
assessment conducted previously, in which ceritinib showed
relatively potent reversible and time-dependent inhibition of
CYP34/5 when incubated with midazolam in HLM assay.
Coadministration of CYP3A substrates with strong
CYP3A inhibitors, such as ceritinib, often requires inclusion of actionable recommendations in the labeling for
the product that is perpetrator of the drug interaction. In
humans, CYP3A subfamily enzymes are the most abundant
cytochrome enzymes and are predominantly expressed in the
liver and intestine, and are involved in the metabolism of a
vast number of key therapeutic drugs (e.g., benzodiazepines,
calcium channel blockers, protease inhibitors, statins) as
well as endogenous compounds (e.g., testosterone, cholesterol). On the basis of new evidence from this clinical pharmacology study, particularly, the major effect of ceritinib on
midazolam pharmacokinetics, co-administration of ceritinib
with sensitive substrates of CYP3A or CYP3A substrates
known to have narrow therapeutic indices (including but
not limited to cyclosporine, dihydroergotamine, ergotamine,
fentanyl, pimozide, quinidine, tacrolimus, alfentanil, and
sirolimus) should be avoided. In cases where concomitant
use is unavoidable due to a medical need, dose reduction of
the CYP3A substrate(s) with an NTI should be considered
by the treating physician, as ceritinib may increase the systemic exposure of such medications to an important extent.
In addition to CYP3A, this study evidenced that ceritinib also inhibits CYP2C9 but to a much lesser extent.
CYP2C9 mediates the metabolism of warfarin, phenytoin, diclofenac, ibuprofen, celecoxib, tolbutamide,
glimepiride, among other commonly prescribed drugs.

13

In addition, CYP2C9 is subject to clinically important
genetic polymorphisms that cause variability in individual
drug response including presence of allele genes associated with deficient enzyme activity (CYP2C9*2/*2, *3/*3,
and *2/*3, commonly referred to as “poor metabolizers”).
Coadministration of ceritinib increased the AUC0-inf
of S-warfarin (the pharmacologically more potent enantiomer) by 54% (90% CI: 36%, 75%) with no change in Cmax
compared to warfarin administered alone, indicating that
ceritinib is a weak inhibitor of CYP2C9. However, considering the medical relevance of warfarin as a commonly
prescribed oral anti-coagulant that has an NTI (i.e., drugs
whose exposure–response relationship indicates that minimal concentration changes may lead to serious safety concerns), an exposure increase by 54% is considered clinically
important given the potential risk of changing the downstream pharmacodynamic effect of warfarin. Furthermore,
an 18% decrease in the metabolite-to-parent AUC ratio for
7-hydroxy-S-warfarin indicates a modest inhibitory effect of
ceritinib on CYP2C9-mediated metabolism of warfarin. The
impact of ceritinib on R-warfarin pharmacokinetics was negligible (Fig. 2, Figure S1). It is worth noting that the comparative statistical analysis for warfarin pharmacokinetics
was performed in the entire dataset that included CYP2C9
extensive, intermediate, and poor metabolizers. As only 1
out of 33 subjects (< 5%) was classified as poor metabolizer
(Table 3), inclusion or not of this single subject would have
had negligible impact to the overall results.
Overall, the frequency, severity, and type of AEs were
consistent with the known safety profile of ceritinib, and no
new safety signals were reported [7, 16]. The efficacy results
for patients with NSCLC in this heavily pretreated patient
population were similar to those observed in previous studies in pretreated patients with ALK-positive NSCLC [7, 16].
In summary, we conducted a multi-center, multiple-dose
drug interaction study to investigate the inhibitory potential
of the ALK-inhibitor ceritinib towards 2 clinically relevant
CYP enzymes, 3A4 and 2C9, using a 2-drug cocktail probe
approach in 33 cancer patients representative of the target
population of ceritinib. The single sequence crossover study
design allowed for the robust pharmacokinetic characterization of midazolam, S- and R-warfarin as well as their metabolites to simultaneously assess CYP3A and 2C9 activity following ceritinib co-administration. The results of this study
indicate that ceritinib, at the clinically recommended dose,
affects the pharmacokinetics of midazolam and warfarin to
different extents. On the basis of new pharmacokinetic and
safety data, revision of dosing recommendations for concomitant use of ceritinib with CYP3A and 2C9 substrates
is warranted. Product labeling should reflect the following:
1. The interaction between ceritinib and CYP3A substrates
is of clinical relevance, particularly sensitive substrates
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(e.g., midazolam, triazolam, alfentanil) or those that
have a NTI (e.g., CYP3A substrates known to prolong
the QT interval).
2. Concomitant use of ceritinib with sensitive substrates
of CYP3A or CYP3A substrates known to have a NTI
should be avoided. If concomitant use is unavoidable,
dose reduction of the CYP3A substrate(s) should be
considered.
3. Concomitant use of ceritinib with sensitive substrates
of CYP2C9 or CYP2C9 substrates for which minimal
concentration changes may lead to serious toxicities
(e.g., warfarin, phenytoin) should be avoided. If concomitant use of such drugs is unavoidable, the prescriber
should consider reducing the dose of the coadministered
CYP2C9 substrate(s).
4. If coadministration with warfarin is unavoidable due to
medical need, it is also recommended to increase the
frequency of international normalized ratio (INR) monitoring as the anti-coagulant effect of warfarin may be
enhanced while the patient is on treatment with ceritinib.
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